TABLE 2.
Comparison of serological indexes in patients
| LVH (N = 100) | Non‐LVH (100) | P value | |
|---|---|---|---|
| RBC (10^12/L) | 4.55 ± 0.39 | 4.59 ± 0.29 | .293 |
| Hb (g/L) | 132.91 ± 15.22 | 136.56 ± 12.64 | .067 |
| HCT (L/L) | 41.77 ± 4.21 | 42.69 ± 3.16 | .082 |
| BUN (mmol/L) | 4.60 ± 1.19 | 4.81 ± 1.30 | .244 |
| CR (μmol/L) | 60.81 ± 9.63 | 59.96 ± 10.34 | .548 |
| TC (mmol/L) | 4.79 ± 0.80 | 4.50 ± 0.97 | .022 |
| TG (mmol/L) | 1.61 ± 0.99 | 2.31 ± 6.57 | .297 |
| LDL‐C (mmol/L) | 2.50 ± 0.61 | 2.64 ± 0.70 | .124 |
| mTOR (ng/mL) | 73.88 ± 16.71 | 68.44 ± 17.20 | .024 |
| PS6K (ng/mL) | 13.37 ± 2.33 | 12.57 ± 2.65 | .024 |
| AR (pg/mL) | 1532.03 ± 268.00 | 1581.09 ± 263.65 | .194 |
| PRL (ng/mL) | 8.01 ± 6.06 | 7.88 ± 3.99 | .863 |
| FSH (mIU/mL) | 61.53 ± 10.89 | 55.18 ± 10.87 | .147 |
| LH (mIU/mL) | 34.43 ± 54.44 | 27.02 ± 33.23 | .247 |
| E2 (pg/mL) | 29.02 ± 0.34 | 29.10 ± 0.05 | .840 |
| PRGE (ng/mL) | 0.22 ± 0.17 | 0.39 ± 0.99 | .099 |
| T (ng/dL) | 21.72 ± 6.19 | 21.02 ± 6.26 | .427 |
| FT (ng/dL) | 3.02 ± 0.76 | 2.57 ± 0.61 | .006 |
| BioT (ng/dL) | 70.52 ± 18.04 | 65.66 ± 14.74 | .038 |
| SHBG (nmol/L) | 115.60 ± 21.64 | 122.66 ± 20.57 | .019 |
| FAI | 0.19 ± 0.06 | 0.17 ± 0.05 | .020 |
Abbreviations: AR, androgen receptor; Bio T, bioavailable testosterone; BUN, blood urea nitrogen; CR, creatinine; E, estradiol; FSH, follicle‐stimulating hormone; FT, free testosterone; FAI, free androgen index; Hb, hemoglobin; HCT, hematocrit; LDL‐C, low‐density lipoprotein cholesterol; LVH, left ventricular hypertrophy; LH, luteinizing hormone; mTOR, mammalian target of rapamycin; PRL, prolactin; PRGE, progesterone; PS6K, phosphorylated ribosome S6 protein kinase; RBC, red blood cell; SHBG, sex hormone–binding globulin; T, testosterone; TC, total cholesterol; TG, triglyceride.